CoChat
Sign Up
Cited by 377Schizophrenia research and treatmentBipolar Disorder and TreatmentTreatment of Major Depression

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Efficacy and Tolerability of Olanzapine, Quetiapine, and Risperidone in the Treatment of Early Psychosis: A Randomized, Double-Blind 52-Week Comparison

McEvoy, Joseph P., Lieberman, Jeffrey A., Perkins, Diana O., Hamer, Robert M., Gu, Hongbin, Lazarus, Arthur, Sweitzer, Dennis, Olexy, Christina, Weiden, Peter, Strakowski, Stephen D.·2007·American Journal of Psychiatry
DOI 10.1176/ajp.2007.164.7.1050
Open this paper in CoChat — free account

Abstract

OBJECTIVE: This 52-week randomized, double-blind, flexible-dose, multicenter study evaluated the overall effectiveness (as measured by treatment discontinuation rates) of olanzapine, quetiapine, and risperidone in patients early in the course of psychotic illness. METHOD: Patients were randomly assigned to treatment with olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day), or risperidone (0.5-4 mg/day) administered in twice-daily doses. Statistical analyses tested for noninferiority in all-cause treatment discontinuation rates up to 52 weeks (primary outcome measure) based on a prespecified noninferiority margin of 20%. RESULTS: A total of 400 patients were randomly assigned to treatment with olanzapine (N=133), quetiapine (N=134), or risperidone (N=133). The mean modal prescribed daily doses were 11.7 mg for olanzapine, 506 mg for quetiapine, and 2.4 mg for risperidone. At week 52, all-cause treatment discontinuation rates were 68.4%, 70.9%, and 71.4% for olanzapine, quetiapine, and risperidone, respectively. Reductions in total score on the Positive and Negative Syndrome Scale (PANSS) were similar for the three treatment groups, but reductions in PANSS positive subscale scores were greater in the olanzapine group (at 12 weeks and at 52 weeks or withdrawal from study) and the risperidone group (at 12 weeks). The most common elicited adverse events for olanzapine were drowsiness (53%), weight gain (51%), and insomnia (38%); for quetiapine, drowsiness (58%), increased sleep hours (42%), and weight gain (40%); and for risperidone, drowsiness (50%), menstrual irregularities in women (47%), and weight gain (41%). CONCLUSIONS: Olanzapine, quetiapine, and risperidone demonstrated comparable effectiveness in early-psychosis patients, as indicated by similar rates of all-cause treatment discontinuation.

Overview

Integrity signals

Registry

Crossref · 10.1176/ajp.2007.164.7.1050

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Research works printed but not linked: 3

  1. Spitzer RL, 1995, Gibbon M
  2. 10.1176/ajp.2006.163.4.600 · DOI
  3. 10.1176/ajp.2006.163.4.611 · DOI

Cited by

Sorted by citations

Items 301–376 of 376

Related

See all

Metadata

Authors
McEvoy, J. P., Lieberman, J. A., Perkins, D. O., Hamer, R. M., Gu, H., Lazarus, A., Sweitzer, D., Olexy, C., Weiden, P., & Strakowski, S. D.
Affiliations
Duke Medical Center (US)
ORCID
Venue
American Journal of Psychiatry
Publisher
American Psychiatric Association Publishing
Published
2007-07
Volume
164
Issue
7
Pages
1050-1060
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
DOI
10.1176/ajp.2007.164.7.1050
OpenAlex
W2156730504
Cited by
377
References
32
Citations by year
2026: 9 · 2025: 3 · 2024: 7 · 2023: 9 · 2022: 19 · 2021: 17 · 2020: 8 · 2019: 13 · 2018: 16 · 2017: 19 · 2016: 19 · 2015: 16 · 2014: 19 · 2013: 27 · 2012: 33
FWCI
22.91
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
early psychosis, olanzapine, quetiapine, risperidone, antipsychotic efficacy, treatment discontinuation, non-inferiority, adverse events, weight gain, sleepiness, PANSS, atypical antipsychotics, long-term antipsychotic treatment, tolerability, menstrual irregularity, insomnia, sleep duration, bipolar disorder
MeSH terms
Quetiapine Fumarate, Olanzapine, Adolescent, Adult, Benzodiazepines, Dibenzothiazepines, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Patient Dropouts, Psychiatric Status Rating Scales, Psychotic Disorders, Schizophrenia, Sleep Wake Disorders, Sleep Stages, Antipsychotic Agents, Weight Gain, Treatment Outcome, Risperidone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review